Intercept To Pay $55M To End Investors' Stock-Drop MDL
Intercept Pharmaceuticals Inc. will fork over $55 million to resolve multidistrict litigation brought by investors accusing it of securities fraud by concealing a liver drug's side effects, according to a stipulation...To view the full article, register now.
Already a subscriber? Click here to view full article